Fig. 4

Effect of cobimetinib on MAPK cascade pathway. Changes in activation status of RAF, MEK and ERK were evaluated in three NB cell lines after treatment with cobimetinib (1 μM) or DMSO for four hours. Cell lysates were made with lysis buffer containing protease and phosphatase inhibitors and probed for total and phospho specific antibodies by western blot analysis. Data presented is representative of three separate experiments